相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang et al.
FRONTIERS OF MEDICINE (2019)
Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope
Laura Orellana et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
Raghupathy Vengoji et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The lncRNA EGFR-AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR-133b/RACK1
Zhi-Qiang Dong et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)
Natalia Asimakopoulou et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study
Xing Wang et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2019)
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Jann N. Sarkaria et al.
NEURO-ONCOLOGY (2018)
MiR-615 inhibits cell proliferation, migration and invasion by targeting EGFR in human glioblastoma
Yanwei Ji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Efficacy and Safety Results of Depatuxizumab Mafodotin (ABT-414) in Patients With Advanced Solid Tumors Likely to Overexpress Epidermal Growth Factor Receptor
Glenwood D. Goss et al.
CANCER (2018)
MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma
Jiale Zhang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development
Tomoyuki Koga et al.
NEURO-ONCOLOGY (2018)
FHL2 interacts with EGFR to promote glioblastoma growth
Lili Sun et al.
ONCOGENE (2018)
Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
William N. William et al.
ONCOLOGIST (2018)
Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
Wojciech Stec et al.
Oncotarget (2018)
Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma
David C. Binder et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
Naoko Matsuda et al.
JAMA ONCOLOGY (2018)
Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes
Yanan Shi et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Gefitinib for advanced non-small cell lung cancer
Esther H. A. Sim et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
TMOD-09. EGFRvIII INCREASES MISMATCH REPAIR PROTEIN EXPRESSION AND IS THEREFORE A PREDICTIVE MARKER FOR TEMOZOLOMIDE RESPONSE IN O6-METHYLGUANINE-DNA METHYLTRANSFERASE NEGATIVE GLIOBLASTOMA CELLS AND TUMORS
Nina Struve et al.
NEURO-ONCOLOGY (2017)
Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles
Jolene Read et al.
EUROPEAN JOURNAL OF CANCER (2017)
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity
Ciro Zanca et al.
GENES & DEVELOPMENT (2017)
CAR T-cell therapy of solid tumors
Carmen S. M. Yong et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy
Cherine Abou-Faycal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Kristen M. Turner et al.
NATURE (2017)
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma
Daniel S. W. Tan et al.
NATURE MEDICINE (2017)
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Juan Manuel Sepulveda-Sanchez et al.
NEURO-ONCOLOGY (2017)
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients
Javier M. Figueroa et al.
NEURO-ONCOLOGY (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner
Silvia Wuerstle et al.
ONCOLOGY LETTERS (2017)
Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
Jennifer P. Newman et al.
NATURE COMMUNICATIONS (2017)
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform
Dong Woo Lee et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma
Joanna Peciak et al.
JOURNAL OF CANCER (2017)
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The Rotation Model
Endang R. Purba et al.
CELLS (2017)
Highly Specific and Effective Targeting of EG FRvIII-Positive Tumors with TandAb Antibodies
Kristina Ellwanger et al.
FRONTIERS IN ONCOLOGY (2017)
EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines
Debyani Chakravarty et al.
SCIENTIFIC REPORTS (2017)
Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Pei-pei Ren et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin van den Bent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
E. E. W. Cohen et al.
ANNALS OF ONCOLOGY (2017)
Glioblastoma-derived cells in vitro unveil the spectrum of drug resistance capability - comparative study of tumour chemosensitivity in different culture systems
Monika Witusik-Perkowska et al.
BIOSCIENCE REPORTS (2017)
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Fang Geng et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Tormod Kyrre Guren et al.
BRITISH JOURNAL OF CANCER (2017)
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer
Julie E. Bauman et al.
JCI INSIGHT (2017)
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Danny Rischin et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Katrin Liffers et al.
TARGETED ONCOLOGY (2016)
Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity
Franz Ricklefs et al.
CANCER RESEARCH (2016)
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study
Shamik Chakraborty et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)
Saulius Cicenas et al.
LUNG CANCER (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2016)
EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line
Cezary Treda et al.
PLOS ONE (2016)
Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes
Wojciech J. Stec et al.
ONCOTARGET (2016)
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib plus /- Vinorelbine
Gerald Goh et al.
PLOS MEDICINE (2016)
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
Marcela V. Maus et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase
Zheng Ruan et al.
BIOCHEMISTRY (2015)
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation
Carlos Stahlhut et al.
CELL CYCLE (2015)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase II study of gefitinib in patients with advanced salivary gland cancers
John A. Jakob et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma
James R. Whittle et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
Ming-Ru Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804)
Hongyun Zhao et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
Ricard Mesia et al.
LANCET ONCOLOGY (2015)
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Edward B. Reilly et al.
MOLECULAR CANCER THERAPEUTICS (2015)
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Kota Iwahori et al.
MOLECULAR THERAPY (2015)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster et al.
NEURO-ONCOLOGY (2015)
Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2015)
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications
S. A. Greenall et al.
ONCOGENE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression
Fulin Xu et al.
TUMOR BIOLOGY (2015)
Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles
Milota Kaluzova et al.
ONCOTARGET (2015)
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential
Marie-Therese Stockhausen et al.
CANCER BIOLOGY & THERAPY (2014)
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib
Antonia Kalykaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III
David R. Emlet et al.
CANCER RESEARCH (2014)
Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity
German G. Gomez et al.
CANCER RESEARCH (2014)
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
Tamas Hickish et al.
EUROPEAN JOURNAL OF CANCER (2014)
Interdependent epidermal growth factor receptor signalling and trafficking
Sylwia Jones et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Quantitative Proteomic Analysis Reveals Effects of Epidermal Growth Factor Receptor (EGFR) on Invasion-promoting Proteins Secreted by Glioblastoma Cells
Vineet Sangar et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
The Failure in the Stabilization of Glioblastoma-Derived Cell Lines: Spontaneous In Vitro Senescence as the Main Culprit
Ewelina Stoczynska-Fidelus et al.
PLOS ONE (2014)
EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
Hongsheng Miao et al.
PLOS ONE (2014)
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
David A. Nathanson et al.
SCIENCE (2014)
EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Joshua M. Francis et al.
CANCER DISCOVERY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor
Nicholas J. Bessman et al.
CELL REPORTS (2014)
Sox2 Promotes Malignancy in Glioblastoma by Regulating Plasticity and Astrocytic Differentiation
Artem D. Berezovsky et al.
NEOPLASIA (2014)
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
D. P. S. Sohal et al.
ANNALS OF ONCOLOGY (2013)
Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures
Karina Kristoffersen et al.
CANCER BIOLOGY & THERAPY (2013)
EGFR Phosphorylates Tumor-Derived EGFRvIll Driving STAT3/5 and Progression in Glioblastoma
Qi-Wen Fan et al.
CANCER CELL (2013)
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation
Rama Krishna Kancha et al.
CELL COMMUNICATION AND SIGNALING (2013)
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2013)
Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter
Khatri Latha et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
Ken-ichi Sato
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Access to the Nucleus and Functional Association with c-Myc Is Required for the Full Oncogenic Potential of ΔEGFR/EGFRvIII
Anupama E. Gururaj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
Characterization of amplification patterns and target genes on the short arm of chromosome 7 in early-stage lung adenocarcinoma
Ji Un Kang
MOLECULAR MEDICINE REPORTS (2013)
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme
D. Yin et al.
ONCOGENE (2013)
EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
C. A. Del Vecchio et al.
ONCOGENE (2013)
Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network
Inka Regine Weingaertner et al.
PLOS ONE (2013)
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
Bryan D. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
Bryan D. Choi et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Regulation of HGF Expression by Delta EGFR-Mediated c-Met Activation in Glioblastoma Cells
Jeannine Garnett et al.
NEOPLASIA (2013)
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
Bryan D. Choi et al.
ONCOIMMUNOLOGY (2013)
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Jin H. Park et al.
BIOCHEMICAL JOURNAL (2012)
Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer
Mark T. Fleming et al.
CLINICAL GENITOURINARY CANCER (2012)
Single Domain Antibodies: A New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting
Kobra Omidfar et al.
DNA AND CELL BIOLOGY (2012)
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
N. S. Horowitz et al.
GYNECOLOGIC ONCOLOGY (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
Janessa J. Laskin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy
Aaron S. Gajadhar et al.
MOLECULAR CANCER RESEARCH (2012)
EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas
Angelique Guillaudeau et al.
PLOS ONE (2012)
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
Jeroen A. J. M. van de Water et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Yongsheng Wang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
J. A. Chan et al.
ANNALS OF ONCOLOGY (2011)
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
S. Iqbal et al.
ANNALS OF ONCOLOGY (2011)
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Matija Snuderl et al.
CANCER CELL (2011)
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
Gianmaria Liccardi et al.
CANCER RESEARCH (2011)
Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
Jeonghee Cho et al.
CANCER RESEARCH (2011)
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
John Farley et al.
GYNECOLOGIC ONCOLOGY (2011)
Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies
Monika Witusik-Perkowska et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Forced Dimerization Increases the Activity of ΔEGFR/EGFRvIII and Enhances Its Oncogenicity
Yeohyeon Hwang et al.
MOLECULAR CANCER RESEARCH (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
Justin D. Lathia et al.
PLOS ONE (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Nicole G. Chau et al.
HEAD & NECK ONCOLOGY (2011)
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Nicola Montano et al.
NEOPLASIA (2011)
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation
Susie I. Ymer et al.
Cancers (2011)
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
A. Jatoi et al.
ANNALS OF ONCOLOGY (2010)
Development of an EGFRvIII specific recombinant antibody
Puja Gupta et al.
BMC BIOTECHNOLOGY (2010)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda et al.
GENES & DEVELOPMENT (2010)
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells
Angel Ayuso-Sacido et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth
Paul H. Huang et al.
MOLECULAR BIOSYSTEMS (2010)
Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status
Xuan Zhou et al.
LABORATORY INVESTIGATION (2010)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors
Piotr Rieske et al.
BMC CANCER (2009)
Interaction of antibodies with ErbB receptor extracellular regions
Karl R. Schmitz et al.
EXPERIMENTAL CELL RESEARCH (2009)
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Michael D. Prados et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma
A. Idbaih et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells
Barry Jutten et al.
RADIOTHERAPY AND ONCOLOGY (2009)
The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases
Vinochani Pillay et al.
NEOPLASIA (2009)
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
Dipa Patel et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
Juliane Weber et al.
BIODRUGS (2008)
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
P. de Graeff et al.
BRITISH JOURNAL OF CANCER (2008)
Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III
Junya Fukai et al.
CANCER SCIENCE (2008)
Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors
Karina Dahl Steffensen et al.
CLINICAL CANCER RESEARCH (2008)
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation
Sara Sigismund et al.
DEVELOPMENTAL CELL (2008)
A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide
U. Lassen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor
Jiefei Tong et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity
Farnaz Yamoutpour et al.
MOLECULAR CANCER THERAPEUTICS (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
EGF receptor ubiquitination is not necessary for its internalization
Fangtian Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
K. Shtiegman et al.
ONCOGENE (2007)
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
Yago Nieto et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
Michael V. Grandal et al.
CARCINOGENESIS (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
M. Schmitz et al.
BRITISH JOURNAL OF CANCER (2007)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
A population of human brain parenchymal cells express markers of glial, neuronal and early neural cells and differentiate into cells of neuronal and glial lineages
Piotr Rieske et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R alpha 2, gp100 and TRP-2 for immunotherapy
Stephan Saikali et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma
Gentao Liu et al.
MOLECULAR CANCER (2006)
Hypophosphorylation of residue Y1045 leads to defective Downregulation of EGFRvIII
Wei Han et al.
CANCER BIOLOGY & THERAPY (2006)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer
Mizutomo Azuma et al.
CLINICAL COLORECTAL CANCER (2006)
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
Shideng Bao et al.
CANCER RESEARCH (2006)
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy
Kelly N. Blehm et al.
CLINICAL CANCER RESEARCH (2006)
Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo
CS Kang et al.
CANCER GENE THERAPY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor
TG Johns et al.
FASEB JOURNAL (2005)
RNA interference against a glioma-derived allele of EGFR induces blockade at G2M
QW Fan et al.
ONCOGENE (2005)
Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo
JL Eller et al.
NEUROSURGERY (2005)
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines
ME Halatsch et al.
JOURNAL OF NEUROSURGERY (2004)
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma
R Galli et al.
CANCER RESEARCH (2004)
EGFR and EGFRvIII expression in primary breast cancer and cell lines
JM Rae et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
RB Luwor et al.
ONCOGENE (2004)
Isolation of cancer stem cells from adult glioblastoma multiforme
XP Yuan et al.
ONCOGENE (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Development of novel targeted therapies in the treatment of malignant glioma
JN Rich et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization
MHH Schmidt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme
XY Luo et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Trafficking of the ErbB receptors and its influence on signaling
HS Wiley
EXPERIMENTAL CELL RESEARCH (2003)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
AA Jungbluth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Expression of constitutively activated EGFRvIII in non-small cell lung cancer
I Okamoto et al.
CANCER SCIENCE (2003)
Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR
A Shir et al.
NATURE BIOTECHNOLOGY (2002)
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro
TN Ignatova et al.
GLIA (2002)
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling
XC Yu et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis
H Ge et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Novel monoclonal antibody specific for the DE2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene
TG Johns et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Glycosylation-induced conformational modification positively regulates receptor-receptor association -: A study with an aberrant epidermal growth factor receptor (EGFRvIII/ΔEGFR) expressed in cancer cells
H Fernandes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA
ME Halatsch et al.
JOURNAL OF NEUROSURGERY (2000)
Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo
PY Pu et al.
JOURNAL OF NEUROSURGERY (2000)
分享论文
